Advanced

Detection of pancreatic cancer using antibody microarray-based serum protein profiling

Ingvarsson, Johan LU ; Wingren, Christer LU ; Carlsson, Anders LU ; Ellmark, Peter LU ; Wahren, Britta; Engström, Gunilla; Harmenberg, Ulrika; Krogh, Morten LU ; Peterson, Carsten LU and Borrebaeck, Carl LU (2008) In Proteomics 8(11). p.2211-2219
Abstract
The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody... (More)
The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Proteomics
volume
8
issue
11
pages
2211 - 2219
publisher
John Wiley & Sons
external identifiers
  • wos:000256961600009
  • scopus:46049092019
ISSN
1615-9861
DOI
10.1002/pmic.200701167
project
CREATE Health
language
English
LU publication?
yes
id
c704cb8c-2481-4cd4-abc9-dac23313d4aa (old id 1039940)
date added to LUP
2008-02-28 13:53:10
date last changed
2017-07-09 03:41:29
@article{c704cb8c-2481-4cd4-abc9-dac23313d4aa,
  abstract     = {The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of &lt;12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.},
  author       = {Ingvarsson, Johan and Wingren, Christer and Carlsson, Anders and Ellmark, Peter and Wahren, Britta and Engström, Gunilla and Harmenberg, Ulrika and Krogh, Morten and Peterson, Carsten and Borrebaeck, Carl},
  issn         = {1615-9861},
  language     = {eng},
  number       = {11},
  pages        = {2211--2219},
  publisher    = {John Wiley & Sons},
  series       = {Proteomics},
  title        = {Detection of pancreatic cancer using antibody microarray-based serum protein profiling},
  url          = {http://dx.doi.org/10.1002/pmic.200701167},
  volume       = {8},
  year         = {2008},
}